Aspen Neuroscience, Inc.: GILEAD SCIENCES, INC. discloses a stake of more than 5% (Schedule 13G)
Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 6 November 2026, by SEC EDGAR SCHEDULE 13G
40
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Gilead Sciences disclosed a stake exceeding 5% in Aspen Neuroscience in a Schedule 13G filing with the SEC (accession 0001123292-26-001496). The exact share count and percentage were not specified in the filing headline. The move signals Gilead's continued interest in Aspen's cell therapy work for Parkinson's disease. Investors should watch for further disclosures detailing the size and nature of the position.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Aspen Neuroscience, Inc., Gilead Sciences, Inc.